Immunotherapy drug cemiplimab takes on rare, incurable cancer
NCT ID NCT07050186
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether the immunotherapy drug cemiplimab can help people with NUT carcinoma, a rare and aggressive cancer that has spread or cannot be removed by surgery. The study will enroll 15 participants and measure how long they live and whether their tumors shrink. Cemiplimab works by helping the body's immune system recognize and attack cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cemiplimab (an immunotherapy drug that helps the immune system attack cancer cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with NUT carcinoma, a rare and aggressive cancer with no current cure.
- What could go wrong
- This is a very small, early-phase trial with only 15 participants. It may not show enough benefit, or side effects could outweigh any gains. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NUT CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.